Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients. The company's advanced pipeline includes zuranolone, a neuroactive steroid, which is presently undergoing Phase III clinical trials for several disorders, such as PPD, major depressive disorders, treatment-resistant depression, generalized anxiety disorders, and bipolar depression.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2025 | -$0.96 | -$0.79 | Beat |
| Apr 29, 2025 | -$0.99 | -$1.01 | Miss |
| Feb 11, 2025 | -$1.54 | -$1.56 | Miss |
| Oct 29, 2024 | -$1.52 | -$1.53 | Miss |
| Jul 31, 2024 | -$1.68 | -$1.70 | Miss |
| Apr 25, 2024 | -$1.63 | -$1.80 | Miss |